Augmedix Forging Strategic Partnerships for an Open Network of Digital Health Solutions
Myndshft, Ellipsis Health, and The Sullivan Group plan to partner with Augmedix to further enhance healthcare enterprise efficiency and patient outcomes through integrations and offerings leveraging structured data, ambient AI, and Augmedix’s bi-directional communication channel into the point of care
SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading, ambient medical documentation and data solutions, announced today that it has reached agreements in principle for strategic collaborations with three innovative digital health companies: Myndshft, Ellipsis Health, and The Sullivan Group. The goal of these partnerships is to enhance the value delivered to health systems by forging an open network of digital health solutions that will integrate into Augmedix’s technology through application programming interfaces (APIs), structured data feeds, and Augmedix’s bi-directional communication channel into the point of care.
“Partnering with these healthcare innovators represents our commitment to drive transformation through open collaborations and integrations,” said Ian Shakil, Founder, Director, and Chief Strategy Officer of Augmedix. “‘The whole is greater than the sum of its parts’ absolutely rings true here. By bringing Augmedix’s platform and our partners’ technologies together, we expect to magnify their impact, further driving our joint missions to tackle the full spectrum of administrative burdens that clinicians face while improving clinician and patient experiences.”
Myndshft, a provider of automated prior authorization software, and Augmedix will work together to take strategic steps to streamline automated, end-to-end documentation. Through this partnership, once Augmedix transfers the medical note to the electronic health record (EHR), Myndshft dynamically references clinicians’ medical documentation, patients’ health and benefits information, and payers’ plans and policies to automate prior authorization submissions on behalf of Augmedix and Myndshft customers. This process allows information such as authorizations, denials, appeals, documentation requests, and status monitoring to be populated back into the EHR, ensuring that the combined services address administrative challenges while offering seamless scaling, integration, and support options.
Ellipsis Health, the market leader in AI-generated vocal biomarker technology for the identification and monitoring of mental health conditions at scale, intends to work with Augmedix to better serve clinicians and patients in need of behavioral healthcare services. Augmedix and Ellipsis Health expect to be able to automate medical documentation, mental health screenings, social determinants of health (SDOH) screenings, and topic analysis to help to identify issues earlier and triage patients to the appropriate care. Augmedix plans to integrate the Ellipsis Health API into its platform so that alongside ambient medical documentation, clinicians will receive patients’ anxiety and depression severity scores during clinical visits. This will allow Augmedix and Ellipsis Health to help improve patient experiences and outcomes.
The Sullivan Group, a leading authority in patient safety and medical error reduction, is partnering with Augmedix to advance this mission. Together, Augmedix and The Sullivan Group plan to offer high-quality, trusted solutions that integrate medical documentation with a reduction in clinicians’ exposure to diagnosis-related errors through the Clinical Decision Support System (CDSS). Diagnosis-related errors are the highest cost driver of malpractice claims in emergency medicine. The partnership will sit at the heart of helping to solve for documentation burden, clinician burnout, and patient safety, especially among emergency departments and ambulatory clinics.
The Augmedix platform harnesses automatic speech recognition, natural language processing, including large language models, and structured data sets. It digitizes the natural conversation between a clinician and patient, extracts the necessary medical information and then converts the information into comprehensive medical notes and structured data in real time. The medical notes are then transferred into the EHR.
These partnerships will expand the benefits of Augmedix’s platform by incorporating prior authorization, clinical decision support, and a system designed to reduce clinician exposure to diagnosis-related medical errors. They will also enable Augmedix to further leverage the wealth of structured data created by its platform and will serve to enhance health system ROI and patient outcomes. The parties have agreed in principle on a strategic partnership pending finalization of a definitive agreement.
For more information, visit https://augmedix.com/partnerships-and-integrations/.
Augmedix (Nasdaq: AUGX) delivers industry-leading, ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners.
Augmedix is on a mission to help clinicians and patients form a human connection by seamlessly integrating our technology at the point of care. Augmedix’s proprietary platform digitizes natural clinician-patient conversations, which are converted into comprehensive medical notes and structured data in real time. The company’s platform uses automatic speech recognition and natural language processing, including large language models, to generate accurate and timely medical notes that are transferred into the EHR.
Augmedix’s products relieve clinicians of administrative burden, in turn, reducing burnout, increasing clinician efficiency and improving patient access. Through Augmedix’s proprietary platform and bi-directional communication channel, Augmedix is ideally suited to serve as the vehicle for change at the point of care.
Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit www.augmedix.com.
This press release contains “forward-looking statements” that involve a number of risks and uncertainties. Words such as “believes,” “may,” “will,” “estimates,” “potential,” “continues,” “anticipates,” “intends,” “expects,” “could,” “would,” “projects,” “plans,” “targets,” “excited,” “optimistic,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the expected benefits of the planned partnerships with Myndshft, Ellipsis Health and The Sullivan Group, including improving patient experiences and outcomes; statements regarding the expected partnerships with Augmedix furthering to enhance healthcare enterprise efficiency and patient outcomes through integrations and offerings leveraging high-quality structured data, ambient AI, and Augmedix’s bi-directional communication channel into the point of care; statements regarding the enhanced value delivered to health systems by forging an open network of digital health solutions; statements regarding the seamless interaction of the digital health solutions with Augmedix’s technology; statements regarding the combination of technologies magnifying their impact and tackling the full spectrum of administrative burdens that clinicians face while improving clinician and patient experiences; statements regarding Augmedix’s and Myndshft’s strategic steps to streamline automated, end-to-end documentation; statements regarding the automation of prior authorization submissions and seamless scaling, integration, and support options; statements regarding the expected partnerships allowing Augmedix to expand the benefits of its platform by including prior authorization, clinical decision support, and reduction in medical errors; statements regarding the intent of Augmedix and Ellipsis to better serve clinicians and patients in need of behavioral healthcare services; statements regarding the ability of Augmedix and Ellipsis Health to automate medical documentation, mental health screenings, SDOH screenings, and topic analysis to help to identify issues earlier and triage patients to the appropriate care; statements regarding Augmedix’s plans to integrate the Ellipsis Health API into its platform to enable clinicians to receive patients’ anxiety and depression severity scores during clinical visits; statements regarding the ability to offer high-quality, trusted solutions that integrate medical documentation with a reduction in clinicians’ exposure to diagnosis-related errors; statements regarding The Sullivan Group partnership sitting at the heart of helping to solve the documentation burden, clinician burnout, and patient safety, especially among emergency departments and ambulatory clinics; statements regarding the expansion of the digital health solutions within the Augmedix platform; statements regarding Augmedix leveraging the wealth of structured data created by its platform to further generate high-value services and substantial ROI; and statements regarding the plan by the parties to enter into definitive strategic partnership agreements and the expectation that the parties will enter into definitive strategic partnership agreements. Actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, the ability of Augmedix and the parties to enter into definitive agreements consistent with the agreement in principle between the parties and the risks detailed in our most recent Form 10-K filed with the U.S. Securities and Exchange Commission on April 17, 2023, as well as other documents that may be filed by us from time to time with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Released October 5, 2023